Basel Medical Group Ltd
BMGLHealthcareNASDAQMedical Care Facilities · Last scanned Oct 23, 2026
Scan Results
Daily timeframePart of the healthcare sector, Basel Medical Group Ltd (BMGL) is listed under Medical Care Facilities. The $7.0M market capitalization puts BMGL squarely in micro-cap range for its industry. The company offers general and subspecialized orthopedic, including trauma and sports medicine services, such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, and minimally invasive orthopedic procedures, as well as neurosurgical treatments.
Market Cap
$7.0M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-5.01
EPS (Fwd)
—
ROE
-147.4%
ROA
-15.5%
Cash
$8.4M
Total Debt
$9.9M
Free CF
-$11.7M
52W Change
-76.4%
Annual Financials
Cash vs Debt
Where BMGL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BMGL finished 34.36% below its 150-day moving average ($6.17) and 39.01% below its 200-day moving average ($6.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMGL overbought or oversold?
At the October 20, 2026 close, BMGL's RSI(14) was 80.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Basel Medical Group Ltd carries $9.9M in total debt against $8.4M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$11.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -147.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $10.7M (2022) to $11.3M (2025).
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BMGL.